We offer many clinical trials for all types of leukemia. Clinical trials test new drugs and new ways of treating patients with leukemia. Our experts conduct these studies to find better treatments. Many clinical trials become the next standard of care. Ask your doctor or nurse if a clinical trial may be right for you.
To determine if a trial is right for you, make an appointment for a consultation. 410.955.8964
For Current Patients
Ask your physician if a trial will be right for you.
Search below for all current open leukemia clinical trials.
Leukemia (AML and ALL and CMML)
EA9152: A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relasped or Refractor T-Cell or B-Cell Acute Lymphoblastic Leukemia
EA9181: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
ETCTN10030: A phase I study of Blinatumomab in combination with checkpoint inhibitor(s) of PD-1 (Nivolumab) or both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in patients with poor-risk, relapsed or refractory CD19+ precursor B-lymphoblastic leukemia
ETCTN10075: Phase IB open label study of AMG-232 in combination with Decitabine in patients with AML
ETCTN10334: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy
J1927: A phase I first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of AMG427 in subjects with relapsed/refractory acute myeloid leukemia (Sponsor: Amgen)
J2004: A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion (Sponsor: Moffit / Incite)